New system sets benchmark in radiation oncology versatility and capabilities
BALTIMORE – The Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences in the Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital (Baltimore, Maryland) has acquired Elekta's Versa HD™ linear accelerator.
The radiation therapy system features the versatility to deliver high-volume conventional techniques, in addition to advanced linear accelerator treatments that require precision targeting.
Versa HD is equipped with the Agility™ 160-leaf multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and improved healthy tissue preservation. With previous beam-shaping technologies, high-definition (HD) beam shaping was limited to small targets. Versa HD with Agility now enables high-definition beam shaping over a significantly larger treatment field, expanding advanced treatments to a broader spectrum of tumors. Combining this novel technology with a new High Dose Rate mode, Versa HD is expected to provide rapid delivery of more sophisticated therapies within standard radiotherapy treatment times.
To learn more about Versa HD, visit www.VersaHD.com.
Versa HD is not available for sale or distribution in all markets.
For further information, please contact:
Director, Investor Relations
Tel: +46 702 100 451
Time zone: CET: Central European Time
Director, Global Public Relations and Brand Management
Tel: +1 770-670-2447
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Web Site: http://www.elekta.com